DANTROLENE SODIUM (dantrolene sodium) by Pfizer is clinical pharmacology: in isolated nerve-muscle preparation, dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. Approved for controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e, the treatment of skeletal muscle spasm resulting from rheumatic disorders, multiple sclerosis and 1 more indications. First approved in 2016.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY: In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates the excitation-contraction coupling, probably by…
Worked on DANTROLENE SODIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.